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Abstract
Histological ‘phenotypic subtypes’ that classify patients into four groups (immune, canonical, latent and stro-
mal) have previously been demonstrated to stratify survival in a stage I–III colorectal cancer (CRC) pilot
cohort. However, clinical utility has not yet been validated. Therefore, this study assessed prognostic value of
these subtypes in additional patient cohorts along with associations with risk of recurrence and response to
chemotherapy. Two independent stage I–III CRC patient cohorts (internal and external cohort) were utilised
to investigate phenotypic subtypes. The primary endpoint was disease-free survival (DFS) and the secondary
endpoint was recurrence risk (RR). Stage II–III patients, from the SCOT adjuvant chemotherapy trial, were
utilised to further validate prognostic value and for exploratory analysis assessing associations with adjuvant
chemotherapy. In an 893-patient internal cohort, phenotypic subtype independently associated with DFS
(p = 0.025) and this was attenuated in stage III patients (p = 0.020). Phenotypic subtype also independently
associated with RR (p < 0.001) in these patients. In a 146-patient external cohort, phenotypic subtype inde-
pendently stratified patients by DFS (p = 0.028), validating their prognostic value. In 1343 SCOT trial
patients, the effect of treatment type significantly depended on phenotypic subtype (pinteraction = 0.011).
Phenotypic subtype independently associated with DFS in stage III patients receiving FOLFOX (p = 0.028).
Furthermore, the immune subtype significantly associated with better response to FOLFOX compared to
CAPOX adjuvant chemotherapy in stage III patients (p = 0.013). In conclusion, histological phenotypic sub-
types are an effective prognostic classification in patients with stage III CRC that associates with risk of
recurrence and response to FOLFOX adjuvant chemotherapy.
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Introduction
There has been an enormous effort to develop a prog-
nostic classification of colorectal cancer (CRC) based
mainly on transcriptomic analysis of tumours
[1,2]. We recently proposed a histological phenotypic
subtyping method based on phenotypic characteristics
of the tumour microenvironment (immune and stromal
infiltrate) and tumour proliferation [3], extrapolated
from the consensus molecular subtypes (CMS), that
could translate more readily to the clinic [1]. This
method classifies into four prognostic groups –
immune, canonical, latent and stromal – in a discovery
cohort of 237 patients with stage I–III CRC [3], but
requires validation.
Establishing distinct patient groups will allow devel-
opment of personalised treatment approaches for CRC,
as evidenced by the use of mismatch repair deficiency
for response to immunotherapy [4]. There is currently
a lack of biomarkers to predict response to adjuvant
chemotherapy, particularly important for CRC and
5-FU-based adjuvant chemotherapy, as the SCOT trial
recently demonstrated that patients receiving CAPOX
(capecitabine and oxaliplatin) have similar survival
with 3- versus 6-months duration, whereas patients
receiving FOLFOX (bolus and infused fluorouracil
with oxaliplatin) require 6-months duration [5]. This
highlights the importance of identifying which patients
need to receive the longer more invasive FOLFOX
regimen compared to the potentially shorter less inva-
sive CAPOX regimen. Histological phenotypic sub-
typing could provide such a tool.
Hence, the primary aim of this study was to validate
the prognostic value of the histological phenotypic
subtypes in distinct stage I–III CRC internal and exter-
nal cohorts. The secondary aim was to assess associa-
tions with risk of recurrence. Finally, the exploratory
aim was to investigate adjuvant chemotherapy in a
subset of stage II–III CRC patients from the SCOT
trial to assess associations with treatment type or
duration.
Methods
Study cohorts
In the internal cohort there were 1030 patients who
had undergone a potentially curative resection for
stage I–III CRC between 1997 and 2007 at the Glas-
gow Royal Infirmary, Western Infirmary or Stobhill
Hospitals (Glasgow, UK, GSH/18/ON/007; Ethics
No. 16/WS/0207). In the external validation cohort,
there were 166 patients who had undergone a poten-
tially curative resection for stage I–III CRC between
1992 and 2016 at St Vincent’s University Hospital
(Dublin, Ireland) or the Academic Medical Center
(Amsterdam, The Netherlands, AMC-AJCCII-90;
Ethics No. W12/011/12.17.0020). In the TransSCOT
cohort there was tissue available from 3000 patients,
derived from the SCOT adjuvant chemotherapy trial
(ISRCTN no. 59757862; 6088 patients) who had
undergone potentially curative resection for high-risk
stage II or stage III CRC between 2008 and 2013
within the UK.
All patients were followed up for at least 3 years
and patients who died within 30 days of surgery, had
no tissue/survival data available or for whom staining
missing were excluded from the analysis, providing
893 eligible patients within the internal cohort, 146 eli-
gible patients within the external validation cohort and
1343 eligible patients within the TransSCOT cohort
(Figure 1). The study complied with the Declaration of
Helsinki and individual ethics committee guidelines. It
was not appropriate to involve patients or the public in
the design, conduct, reporting or dissemination of this
research.
Patient cohort clinicopathological characteristics
Tumours were staged using the fifth edition (UK) or
seventh edition (Amsterdam and Dublin) of the AJCC/
UICC-TNM staging system. In the internal cohort, the
presence of venous invasion was assessed using
elastica staining. Tumour differentiation was graded as
well/moderate or poor in accordance with Royal Col-
lege of Pathologists guidelines [6] and additional data
were taken from pathology reports. Mismatch repair
status was available for the internal and external vali-
dation cohorts. Following surgery, patients with stage
III or high-risk stage II disease and without significant
co-morbid disease precluding adjuvant treatment were
considered for 5-fluorouracil-based chemotherapy. For
the TransSCOT cohort, all patients were treated with
FOLFOX (bolus and infused fluorouracil with
oxaliplatin) or CAPOX (capecitabine and oxaliplatin)
adjuvant chemotherapy randomised to 3- or 6-months
duration. Date and site of recurrence and cause of
death were crosschecked using electronic case records.
Assessment of phenotypic subtypes
Phenotypic subtype measures were assessed on full
sections taken from the deepest point of invasion. For
the internal, Amsterdam and TransSCOT cohorts,
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slides were assessed by a single observer (AKR or
JHP) with 10% co-scored by the other observer; inter-
class correlation coefficient was >0.7 for all markers.
The classification was externally validated by an inde-
pendent observer (SA) at St Vincent’s Hospital, Dub-
lin, with 10% co-scored by a second observer (AKR);
interclass correlation coefficient was >0.7 for all
markers. Local inflammatory cell infiltrate was visu-
ally assessed using the Klintrup–Makinen (KM) grade
[7]. Briefly, the KM grade was assessed on a H&E
section at the invasive margin; a score of 0–1
(no increase or mild/patchy increase in inflammatory
cells) was graded as weak and a score of 2–3 (promi-
nent inflammatory reaction forming a band at the inva-
sive margin, or florid cup-like infiltrate at the invasive
edge with destruction of cancer cell islands) was
graded as strong. Stromal invasion was visually
assessed using tumour stroma percentage (TSP) on an
H&E section with a cut-off value of 50% for low
(≤50% stroma present) and high (>50% stroma pre-
sent) [8]. Proliferation rate was assessed using Ki67
proliferation index with automated hotspot cell counts
within a single pre-determined field of view at ×400
magnification utilising the SlidePath digital image hub
(Leica, UK). Proliferation rate cut-offs were assessed
by receiver operating characteristic (ROC) analysis in
the internal cohort and 30% deemed to be the optimal
cut-off. Proliferation was graded as low (≤30%) or
high (>30%).
Study endpoints
The primary endpoint was disease-free survival (DFS;
measured from date of surgery/randomisation to date
of recurrence at any location or death from any cause).
The secondary endpoint was recurrence risk (RR: mea-
sured from date of surgery/randomisation to date of
recurrence at any location or death from CRC). The
Figure 1 Consort diagram for the patient cohorts. Flow diagram showing criteria for exclusion of patients from the study comparing the
three cohorts; internal cohort, external validation cohort and TransSCOT cohort.
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exploratory endpoint was associations with adjuvant
chemotherapy type and duration.
Statistical analysis
The prospectively powered outcome analysis com-
pared the immune (37%) and stromal (19%) subtypes.
By using a two-sided α = 0.05 analysis and assuming
a hazard ratio (HR) of 2.0 and an immune subtype
prevalence of 37%, a sample size of >225 patients
gave >90% power to detect a survival difference
between the immune and stromal subtypes. SPSS (ver-
sion 25; IBM, New York, NY, USA) was used for sta-
tistical analysis. Kaplan–Meier and log-rank analysis
compared DFS or RR (adjusted for T-stage, N-stage
and treatment duration when assessing chemotherapy
interactions). The log-rank for overall trend was
reported for all DFS and RR survival analysis. HRs
and CIs were calculated from univariate Cox regres-
sion survival analysis. Multivariable Cox regression
survival analysis using a backward conditional elimina-
tion model and a statistical significance threshold of
P value less than 0.1 was performed to identify indepen-
dent prognostic biomarkers. A Cox proportional hazards
interaction model was performed to assess interactions
between phenotypic subtype and treatment type/duration.
The study conformed to the REMARK guidelines [9]
and statistical significance was set at P value less than
0.05. All statistical tests were two-sided.
Results
The internal cohort (n = 893) was utilised to validate the
prognostic utility of the phenotypic subtypes in stage I–III
CRC patients (for cohort characteristics, see supplemen-
tary material, Table S1). No adjuvant therapy data was
available. Median follow-up was 11.3 years (range 6.2–-
16.0 years) with 256 cancer deaths, 287 non-cancer deaths
and a 33% recurrence rate. 305 (34%) patients had an
immune subtype, 248 (28%) a canonical subtype,
186 (21%) a latent subtype and 154 (17%) a stromal sub-
type. The immune, canonical and latent subtypes con-
tained older patients with earlier stage cancer, however,
the stromal subtype contained younger patients with later
stage cancer (see supplementary material, Figure S1).
To ensure the hierarchy of the phenotypic subtype
classification developed in the pilot study was robust,
the three markers utilised were entered into multivari-
ate analysis (see supplementary material, Table S2,
n = 881) with KM grade (p = 0.002) and TSP
(p = 0.073) but not Ki67 (p = 0.971) demonstrated to
be independently prognostic for DFS. The hierarchy of
the three markers was KM grade being considered first
as it was independently prognostic for DFS, then TSP
as it was trending towards being independently prog-
nostic for DFS and finally Ki67 as it showed depen-
dence on the other two markers. Hence, phenotypic
subtype was defined as follows for all cohorts
(Table 1): Immune – High KM-grade, any TSP and
any Ki67; stromal – low KM grade, high TSP and any
Ki67; canonical – low KM-grade, low TSP and high
Ki67; and latent – low for all three markers.
To address the primary endpoint, associations with
DFS were assessed (Figure 2A–C). Phenotypic sub-
type was shown to significantly stratify DFS (HR 1.15
95% CI 1.07–1.24, p = 0.002; Figure 2A), with the
immune subtype having the best outcome and the stro-
mal subtype the worst outcome. To investigate the
phenotypic subtypes in important disease stages,
patients were stratified into stage II or stage III disease.
Phenotypic subtype did not stratify DFS in stage II
CRC (HR 1.05 95% CI 0.93–1.18; Figure 2B); how-
ever, they did significantly associate with DFS in stage
III CRC, with the immune subtype having significantly
improved survival (HR 1.17 95% CI 1.04–1.31,
p = 0.004; Figure 2C). Next to address the secondary
endpoint, associations with RR were assessed
(Figure 2D–F). Phenotypic subtype significantly asso-
ciated with RR, with the immune subtype having a
low risk and the stromal subtype having the highest
risk (HR 1.40 95% CI 1.27–1.56, p < 0.001;
Figure 1D). When assessing important disease stages,
phenotypic subtype associated with RR in both stage
II (HR 1.44 95% CI 1.20–1.72, p < 0.001; Figure 2E)
and stage III (HR 1.19 95% CI 1.04–1.36, p = 0.004;
Figure 2F) CRC. In stage II disease, only patients with
a stromal subtype had a high risk of recurrence
whereas, in stage III disease, canonical, latent and stro-
mal patients were all at risk of recurrence.
To assess the phenotypic subtypes as an indepen-
dent prognostic factor, the relationship between
Table 1 Phenotypic subtype classification
Immune Canonical Latent Stromal
Intra-tumour immune infiltrate (KM grade; 0–1/2–3) High Low Low Low
Stromal invasion (TSP; ≤50%/>50%) Any Low Low High
Proliferation rate (Ki67; ≤30%/>30%) Any High Low Any
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phenotypic subtype, common clinical factors and DFS
or RR was examined in multivariate analysis
(Table 2). For DFS in the full cohort (n = 893), age
(p < 0.001), N-stage (p < 0.001), vascular invasion
(p = 0.008), peritoneal involvement (p < 0.001),
tumour necrosis (p = 0.025) and phenotypic subtype
(p = 0.025) were independently prognostic. In stage II
disease (n = 437), only age (p < 0.001) remained inde-
pendently prognostic. However, in stage III disease
(n = 329), age (p = 0.004), T-stage (p = 0.020), differen-
tiation (p = 0.016), vascular invasion (p = 0.026), tumour
perforation (p < 0.001) and phenotypic subtype
(p = 0.020) remained independently prognostic. There-
fore, phenotypic subtype is only an independent prog-
nostic factor in stage III disease for DFS. For RR in the
full cohort, N-stage (p < 0.001), vascular invasion
(p = 0.002), peritoneal involvement (p < 0.001),
tumour perforation (p = 0.004) and phenotypic sub-
type (p < 0.001) were independent risk factors for
recurrence. In stage II disease, only peritoneal
involvement (p = 0.008) and phenotypic subtype
(p < 0.001) remained independent risk factors for
recurrence. Whereas in stage III disease, differentia-
tion (p = 0.010), vascular invasion (p = 0.012), peri-
toneal involvement (p < 0.001), tumour perforation
(p = 0.001) and phenotypic subtype (p = 0.011)
remained independent risk factors for recurrence.
Therefore, phenotypic subtype is a risk factor for
recurrence in all patients with stage I–III CRC.
External validation of the phenotypic subtypes was
performed to assess the validity and translation of the
subtypes within an independent laboratory. The external
validation cohort contained 146 patients with the major-
ity having stage II CRC (86%) allowing validation of
the internal cohort results in an up-to-date early stage
cohort (for cohort characteristics; see supplementary
material, Table S1). Median follow-up was 3.5 years
(range 1.0–9.9 years) with 22 deaths and a 22% recur-
rence rate. 61 (42%) patients had an immune subtype,
55 (38%) a canonical subtype, 12 (8%) a latent subtype
Figure 2 Phenotypic subtype stratifies survival and recurrence risk in stage I–III CRC patients within the internal cohort. (A–C)Kaplan–
Meier curves showing association between phenotypic subtypes and disease-free survival in patients with (A) stage I–III CRC (n = 893),
(B) stage II CRC (n = 437) and (C) stage III CRC (n = 329). (D–F)Kaplan–Meier curves showing association between phenotypic subtypes
and recurrence risk in patients with (D) stage I–III CRC (n = 893), (E) stage II CRC (n = 437) and (F) stage III CRC (n = 329).
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and 18 (12%) a stromal subtype (see supplementary
material, Table S1). Phenotypic subtype significantly
stratified patients by DFS (HR 1.41 95% CI 1.08–1.84,
p = 0.006; Figure 3A), with the stromal subtype having
the worst outcome. Under multivariate analysis with
TNM-stage and mismatch repair status (see supplemen-
tary material, Table S3), only phenotypic subtype
(p = 0.028) was independently prognostic for DFS.
To validate the stage III findings in an up-to-date
cohort, a subset of patients from the SCOT trial, the
TransSCOT cohort, was utilised as it contained a high
proportion of stage III patients (83%) with differing adju-
vant chemotherapy regimens and durations (for cohort
characteristics; see supplementary material, Table S1).
All patients received FOLFOX or CAPOX adjuvant che-
motherapy for at least 3 months. Median follow up was
3.0 years (range 0–7.0 years) with 339 DFS events.
208 (15%) patients had an immune subtype, 547 (41%)
a canonical subtype, 197 (15%) a latent subtype and
391 (29%) a stromal subtype. To ensure this was repre-
sentative of the full SCOT trial cohort, patient character-
istics were compared (see supplementary material,
Table S1). Both cohorts had a similar proportion of
males, stage, and DFS events; the only difference was
that the TranSCOT cohort had fewer rectal cancers.
Therefore, the TranSCOT cohort is a reasonable repre-
sentation of the overall trial population.
Phenotypic subtype significantly stratified patients
by DFS (HR 1.19 95% CI 1.07–1.31, p = 0.008;
Figure 3B), with the stromal subtype having the worst
outcome. When stratified for TNM-stage, phenotypic
subtype did not associate with DFS in stage II disease
(HR 1.05 95% CI 0.78–1.84, p = 0.522; Figure 3C)
but did significantly associate with DFS in stage III
disease (HR 1.21 95% CI 1.08–1.34, p = 0.005;
Figure 3D) similar to the internal validation cohort.
To address the exploratory endpoint, phenotypic
subtype was interrogated for associations with adju-
vant chemotherapy type and duration. Multivariate cox
proportional hazards analysis to assess interactions
between phenotypic subtypes and chemotherapy type
or duration was performed (see supplementary mate-
rial, Table S4). An interaction between phenotypic
subtypes and chemotherapy type (CAPOX versus
FOLFOX; pinteraction = 0.011) was observed but
not with duration (3 months versus 6 months;
pinteraction = 0.809). As the effect of chemotherapy
type depends on phenotypic subtype, associations
with DFS were assessed in patients stratified for chemo-
therapy type (Figure 4; adjusted for T-stage, N-stage and
treatment duration). In patients receiving FOLFOX adju-
vant chemotherapy, phenotypic subtype significantly
stratified DFS (HR 1.40 95% CI 1.16–1.68, p < 0.001;Ta
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Figure 4A) with the immune subtype having the best
outcome. No difference in DFS was noted in patients
receiving CAPOX adjuvant chemotherapy (HR 0.98
95% CI 0.87–1.11, p = 0.745; Figure 4B). Furthermore,
when differences in DFS were assessed between treat-
ment types stratified by phenotypic subtype, the immune
subtype showed a significant difference in DFS between
the two regimens (HR 1.67 95% CI 1.09–2.58,
p = 0.019; Figure 4C) with patients receiving FOLFOX
adjuvant chemotherapy having improved outcomes. No
differences in DFS between the two regimens were seen
within any other phenotypic subtype (Figure 4D–F). As
phenotypic subtype specifically stratified stage III
patients within the full cohort, cox proportional hazards
interaction analysis was repeated within stage II and
stage III patients (see supplementary material, Table S4).
No interactions with phenotypic subtype and treatment
duration were seen for either stage. However, phenotypic
subtype did interact with treatment type in stage III dis-
ease (CAPOX versus FOLFOX; pinteraction = 0.031).
Therefore, patients were stratified into stage II and III dis-
ease (see supplementary material, Figure S2; adjusted for
treatment duration). For patients receiving FOLFOX, DFS
only associated with phenotypic subtype in stage III dis-
ease (HR 1.45 95% CI 1.20–1.76, p < 0.001; see supple-
mentary material, Figure S2B). Furthermore, for patients
with an immune subtype (see supplementary material,
Figure S2C,D), treatment type only associated with DFS
in stage III disease (HR 1.82 95% CI 1.13–2.91,
p = 0.013; see supplementary material, Figure S2D).
Phenotypic subtype was then taken forward into
multivariate analysis with clinical and therapeutic fac-
tors for DFS (Table 3). When assessing any treatment,
phenotypic subtype was not independently prognostic
in the full cohort (p = 0.374) or when restricted to only
stage III patients (p = 0.262) compared to T-stage and
N-stage. Phenotypic subtype was also not indepen-
dently prognostic in any patient groups receiving
CAPOX. However, for patients receiving FOLFOX,
T-stage (p = 0.018), N-stage (p < 0.001) and
Figure 3 External validation confirming that phenotypic subtype stratifies disease-free survival in patients with stage I–III CRC. (A,B)
Kaplan–Meier curves comparing associations of phenotypic subtypes and disease-free survival in (A) an external validation cohort (n = 146)
and (B) the TransSCOT adjuvant chemotherapy cohort (n = 1343). (C,D) Kaplan–Meier curves comparing associations of phenotypic subtypes
and disease-free survival in (C) stage II (n = 231) and (D) stage III (n = 1107) patients from the TransSCOT adjuvant chemotherapy cohort.
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phenotypic subtype (p = 0.008) were independently
prognostic. Similar results were observed for stage III
patients receiving FOLFOX, T-stage (p = 0.046), N-
stage (p = 0.001) and phenotypic subtype (p = 0.028)
were independently prognostic.
Discussion
The results of the present study validate that, in the gen-
eral population, histological phenotypic subtypes are an
effective independent prognostic classification for patients
with stage III CRC. Furthermore, phenotypic subtype can
independently stratify RR across stage I–III CRC, with the
stromal subtype having the highest risk of recurrence. The
exploratory adjuvant chemotherapy analysis suggests that
phenotypic subtype is an independent prognostic classifi-
cation for stage III patients receiving FOLFOX. Interest-
ingly, stage III patients with an immune subtype appear to
respond better to FOLFOX compared to CAPOX adju-
vant chemotherapy, although this exploratory analysis
requires validation in an independent cohort.
Figure 4 The immune subtype predicts response to FOLFOX compared to CAPOX adjuvant chemotherapy in the TransSCOT cohort
(n = 1343). (A,B) Kaplan–Meier curves showing association of phenotypic subtype with disease-free survival for patients receiving
(A) FOLFOX (n = 411) or (B) CAPOX (n = 932) adjuvant chemotherapy within the TransSCOT cohort. (C–F)Kaplan–Meier curves showing
association of chemotherapy type with disease free survival for patients with an (C) immune (n = 208), (D) canonical (n = 547),
(E) latent (n = 197) or (F) stromal (n = 391) subtype.
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Phenotypic subtype was independently associated
with DFS in stage I–III CRC patients from the internal
and external validation cohorts. This was attenuated in
stage III patients but lost in stage II patients,
suggesting this classification may have more utility in
later stage disease, and may aid clinicians when
assessing adjuvant therapy. Interestingly, the immune
and stromal subtype showed similar prognosis at all
stages, whereas prognosis was significantly worse in
stage III tumours for the canonical and latent subtypes.
This agrees with previous studies reporting that TSP
associates with poor prognosis in CRC and other can-
cers independent of stage [8,10–12]. Similarly, high
intra-tumoural lymphocytic infiltrate has previously
been reported to associate with improved survival in
CRC patients independent of stage [13–17]. However,
survival effects for Ki67 proliferation rate vary in the
literature suggesting that prognostic effects are depen-
dent on other clinical factors as demonstrated by a lack
of independence in multivariate analysis [18,19]. How-
]. However, this change in the prognosis of the canoni-
cal and latent subtypes from stage II (good prognosis)
to stage III (poor prognosis) disease is significant for
patients, as the stage II data would suggest minimal
intervention. However, if the patient recurs and pro-
gresses to stage III disease it may be too late for inter-
vention. Therefore, should these patients be put
forward for adjuvant therapy for stage II disease due
to their potential future prognosis if their disease
recurs and progresses?
To address this further, the current study assessed
RR for the phenotypic subtypes. Phenotypic subtype
independently associated with risk of recurrence across
all patients with stage I–III CRC, with the stromal sub-
type having the highest risk of recurrence and the
immune subtype the lowest risk. This could be
expected as TSP is known to associate with epithelial-
to-mesenchymal transition (EMT) and invasion, which
prepares the tumour for metastasis [8]. Therefore, any
residual cells in stromal subtype tumours are likely to
have undergone EMT and be primed for recurrence.
However, similar to DFS, the canonical and latent sub-
types had a low risk in stage II but a high risk in stage
III disease. As both subtypes have a similar change,
this suggests the effect is not dependent on prolifera-
tion rate, but potentially the low levels of immune
infiltrate and stroma within the two groups. This is in
line with previous findings where a low inflammatory
infiltrate in stage III disease led to an unfavourable
prognosis but no difference was seen between low
and high immune infiltrate in stage II disease
[20,21]. Similar changes are not seen for low stroma
[12], suggesting this difference may be influenced byTa
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the low immune infiltrate. This effect can be further
seen in our stage II external validation cohort, where
the immune, canonical and latent subtypes have a
good prognosis whereas the stromal subtype has a
poor prognosis similar to the internal cohort.
One difference between the results of the internal
and external validation cohorts is that phenotypic sub-
type is an independent prognostic factor for the stage
II external cohort but not for stage II patients in the
internal cohort. This difference may be due to the ages
of the cohorts, with the external cohort containing
more recent patients with up-to-date adjuvant thera-
pies. Furthermore, due to constraints on data available
for the external cohort, only TNM-stage and mismatch
repair status are included in the analysis compared to
multiple clinical factors for the internal cohort. There-
fore, if more clinical factors were available for the
external cohort this independence may be lost. Never-
theless, the external cohort validates the prognostic
effect seen in the internal cohort and the translation of
the method to an independent laboratory.
To assess if modern adjuvant chemotherapy regi-
mens affect the prognostic value of the phenotypic
subtypes, they were assessed in a subset of patients
from the SCOT trial. In the TransSCOT cohort, pheno-
typic subtype could stratify DFS; however, this was
not independent of other clinical factors suggesting
that the adjuvant chemotherapy regimens are
diminishing the prognostic effect of the subtypes.
When stratified for stage, high risk stage II patients
had improved DFS across all subtypes suggesting that
these patients respond well to the treatment indepen-
dent of subtype. Whereas, in stage III patients, with
poorer DFS, a significant difference in response to
chemotherapy is observed, but again this was not inde-
pendent of other clinical factors.
To decipher if this loss of independent prognostic
power was due to a specific treatment type or duration,
interactions were investigated. A significant interaction
was observed with chemotherapy type (CAPOX ver-
sus FOLFOX) but not duration (3 versus 6 months)
suggesting it may be a specific type of adjuvant che-
motherapy that is affecting the prognostic value of the
subtypes. No survival difference was seen for patients
receiving CAPOX suggesting that all subtypes had a
similar response to this adjuvant therapy. However, a
significant independent difference in DFS was noted
for patients receiving FOLFOX, with immune patients
doing significantly better compared to other subtypes,
similar to stage III patients in the internal cohorts. Fur-
thermore, when FOLFOX patients where stratified for
stage, only stage III patients had an independent asso-
ciation with DFS, consistent with the other cohorts.
This makes sense as the internal cohort patients were
likely to have been treated with 5-FU chemotherapy as
used in this regimen and the external cohort was
treated with a mixture of 5-FU and FOLFOX-based
regimens. However, CAPOX utilises an oral version,
capecitabine, that is metabolised to 5-FU, so poten-
tially this metabolic interaction may be interacting
with components utilised to define the phenotypic
subtypes.
To assess if the prognostic difference between the
two treatment types was due to a specific subtype,
patients were stratified into the four subtypes. Patients
with an immune subtype did significantly better on
FOLFOX compared to CAPOX especially in stage III
patients, whereas patients with a stromal subtype
trended towards better survival on CAPOX. Validation
of these observations is required, but suggest it is the
adaptive immune cells that interact differently with the
two chemotherapy regimens. When immune cells are
high and infiltrating the tumour as seen in the immune
subtype, FOLFOX is favourable; however, when
excluded, as seen in the stromal subtype, CAPOX is
favourable, agreeing with previous literature reporting
that patients with high tumour-infiltrating and circulat-
ing lymphocytes had significantly improved survival
when receiving FOLFOX [22–24]. One hypothesis
may be that, for CAPOX, the high levels of immune
cells hamper the final stage of metabolism of
capecitabine inhibiting its cytotoxic effect. If this
observation is validated, the immune subtype is a
promising marker to identify patients more likely to
benefit from FOLFOX rather than CAPOX adjuvant
chemotherapy.
This is the first histological CRC subtyping method
to have independent prognostic power in stage III
patients as well as associations with risk of recur-
rence and adjuvant chemotherapy. The method also
utilises sections routinely prepared within clinical
pathology laboratories making it easy to translate to
clinical practice. As well as being readily translated
to clinical practice and being cost effective, pheno-
typic subtype can also classify all patient tumours,
unlike the CMS classification where 20% of tumours
are unclassifiable [1]. Phenotypic subtype assesses
cell types within the tumour and microenvironment
separately whereas the CMS classification looks at all
cell types together. In contrast, the cancer-cell intrin-
sic subtypes only utilise tumour-cell specific trans-
criptomic analysis, which the author suggests
alleviates any issues with tumour heterogeneity [2];
however, this ignores the tumour microenvironment
known to be vital for both anti-tumour and pro-
tumour mechanisms. The phenotypic subtypes take
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all of this into account in a simple, readily translated
and cost-effective way utilising routine clinical
methods, unlike the above transcriptomic-based clas-
sifiers, which have failed to be translated into clinical
practice due to issues with robustness/reproducibility,
turnaround time, and high associated costs.
In conclusion, in the general population, the histo-
logical phenotypic subtype classification has inde-
pendent prognostic power for patients with stage III
CRC. Furthermore, phenotypic subtype can predict
risk of recurrence for these patients, with the
immune subtype having a significantly diminished
risk compared to the other three subtypes. In an
adjuvant chemotherapy trial population, phenotypic
subtype may independently predict response to
FOLFOX adjuvant chemotherapy within stage III
patients, with the immune subtype having a better
response to this treatment when compared to
CAPOX. Going forward, the utility of these sub-
types will be distinguishing the optimal treatments
for each group, including established therapeutics or
the development of novel interventions. Another
important area of research is to develop a digital
pathology approach to distinguish the phenotypic
subtypes utilising deep learning to allow a quick
automated analysis of the patient tissue, either by
automating and integrating the current manual
approaches or developing surrogate markers utilising
neural classification networks. Upon further valida-
tion, the histological phenotypic subtype classifica-
tion could be a useful aid in the clinic for CRC
prognosis, particularly for stage III disease, identi-
fying patients with a risk of recurrence and patients
who could benefit from FOLFOX adjuvant
chemotherapy.
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